Omeros Corporation (OMER) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Omeros Corporation (OMER) Healthcare & Pipeline Overview

Omeros Corporation is a commercial-stage biopharmaceutical company specializing in small-molecule and protein therapeutics for orphan indications. Targeting inflammation, complement-mediated diseases, and cancers, Omeros distinguishes itself through its focus on unmet medical needs and a diverse pipeline of clinical and preclinical programs.

What Is the Investment Thesis for OMER?

Omeros Corporation presents a compelling investment thesis based on its diverse pipeline of clinical and preclinical programs targeting significant unmet medical needs. Narsoplimab, with its advanced clinical development for HSCT-TMA, IgAN, and aHUS, represents a near-term value driver. The company's focus on complement-mediated diseases and addiction disorders provides exposure to high-growth therapeutic areas. Key catalysts include the progression of OMS721 through Phase III trials and potential regulatory approvals. However, investors should be aware of the risks associated with clinical trial outcomes and regulatory hurdles, as well as the competitive landscape in the biotechnology sector. With a market capitalization of $1.35B and a beta of 2.53, Omeros offers both high potential and significant risk.

Based on FMP financials and quantitative analysis

OMER Key Highlights

Market Cap of $1.35B reflects investor valuation of Omeros's pipeline and commercial prospects.

• Beta of 2.53 indicates high volatility compared to the market, typical for biotechnology companies.
• Focus on orphan indications provides potential for accelerated regulatory pathways and market exclusivity.
• Narsoplimab (OMS721/MASP-2) in Phase III trials represents a near-term catalyst for potential revenue generation.
• Diverse pipeline targeting inflammation, complement-mediated diseases, and addiction disorders reduces reliance on a single therapeutic area.

Who Are OMER's Competitors?

OMER is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OMER's Key Strengths?

Diverse pipeline of clinical and preclinical programs.

• Focus on orphan indications with unmet medical needs.
• Proprietary technology platforms for drug discovery.
• Experienced management team with expertise in drug development.

What Are OMER's Weaknesses?

Reliance on clinical trial outcomes for product approvals.

• High cash burn rate due to R&D expenses.
• Dependence on regulatory approvals for commercialization.
• Competition from larger pharmaceutical companies.

What Could Drive OMER Stock Higher?

Narsoplimab (OMS721/MASP-2) Phase III trial results for IgAN.

• Narsoplimab (OMS721/MASP-2) Phase III trial results for aHUS.
• Enrollment and progression of PPAR? (OMS405) Phase II clinical trial for addiction.
• Advancement of PDE7 (OMS527) Phase I clinical trial for addiction and movement disorders.
• Development of MASP-3 (OMS906) Phase I clinical trial for PNH and other alternative pathway disorders.

What Are the Key Risks for OMER?

Financial-distress signal — its Altman Z-Score of 0.12 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-54.4%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures for key drug candidates.
• Regulatory delays or rejections for product approvals.
• Competition from existing and emerging therapies.
• High cash burn rate and need for additional financing.
• Dependence on intellectual property protection for market exclusivity.

What Are the Growth Opportunities for OMER?

• Narsoplimab (OMS721/MASP-2) for IgAN: The Phase III clinical trial for IgAN represents a significant growth opportunity. IgAN is a leading cause of kidney failure, and there is a high unmet need for effective treatments. Successful trial outcomes and regulatory approval could lead to substantial revenue growth. The market for IgAN treatments is projected to reach $1 billion by 2028, offering a substantial commercial opportunity for Omeros.
• Narsoplimab (OMS721/MASP-2) for aHUS: The Phase III clinical trial for aHUS also presents a significant growth opportunity. aHUS is a rare and life-threatening disease, and there are limited treatment options available. Positive trial results and regulatory approval could drive significant revenue growth. The global aHUS market is expected to grow, driven by increased awareness and improved diagnostics.
• PPAR? (OMS405) for Addiction: The Phase II clinical trial for opioid and nicotine addiction represents a promising growth avenue. Addiction is a widespread and costly problem, and there is a growing need for effective treatments. Successful trial results could lead to a valuable therapeutic option. The addiction treatment market is expected to grow, driven by increasing rates of substance abuse and mental health disorders.
• PDE7 (OMS527) for Addiction and Movement Disorders: The Phase I clinical trial for addiction and compulsive disorders, and movement disorders, offers long-term growth potential. These disorders represent significant unmet medical needs, and successful development of PDE7 inhibitors could lead to novel therapeutic options. The market for addiction and movement disorder treatments is substantial and growing.
• MASP-3 (OMS906) for PNH and Other Alternative Pathway Disorders: The Phase I clinical trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders represents a strategic growth opportunity. PNH is a rare and chronic disease, and there is a need for more effective and convenient treatments. Successful development of MASP-3 inhibitors could provide a competitive advantage. The PNH market is expected to grow, driven by advancements in diagnosis and treatment.

What Opportunities Does OMER Have?

• Expansion of pipeline through strategic acquisitions or partnerships.
• Potential for accelerated regulatory pathways for orphan indications.
• Growing market for complement-mediated disease therapies.
• Increasing demand for addiction treatment options.

What Threats Does OMER Face?

• Clinical trial failures can significantly impact valuation.
• Regulatory setbacks can delay or prevent product approvals.
• Competition from biosimilars and generic drugs.
• Changes in healthcare policies and reimbursement models.

What Are OMER's Competitive Advantages?

• Patented therapeutic compounds provide market exclusivity.
• Focus on orphan indications allows for accelerated regulatory pathways.
• Specialized expertise in complement-mediated diseases.
• Proprietary technology platforms for drug discovery and development.

What Does OMER Do?

Omeros Corporation, founded in 1994 and headquartered in Seattle, Washington, is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics. The company focuses on addressing unmet medical needs in areas such as inflammation, complement-mediated diseases, cancers related to immune system dysfunction, and addictive and compulsive disorders. Omeros's pipeline includes both small-molecule and protein therapeutics, with several programs in various stages of clinical development. A key asset is Narsoplimab (OMS721/MASP-2), which has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is in Phase III clinical trials for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS). Additionally, Omeros is developing PPAR? (OMS405) for opioid and nicotine addiction, PDE7 (OMS527) for addiction and compulsive disorders, and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company also has a robust preclinical program focused on MASP-2 and MASP-3 inhibitors, GPR174 Inhibitors, and Chimeric Antigen Receptor (CAR) T-Cell therapies. Omeros aims to improve patient outcomes by targeting the root causes of complex diseases through innovative scientific approaches.

What Products and Services Does OMER Offer?

• Discovers small-molecule therapeutics.
• Develops protein therapeutics.
• Commercializes therapeutics for orphan indications.
• Targets inflammation and complement-mediated diseases.
• Develops therapies for cancers related to immune system dysfunction.
• Creates treatments for addictive and compulsive disorders.

How Does OMER Make Money?

• Develops and patents novel therapeutic compounds.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved products through direct sales or partnerships.

What Industry Does OMER Operate In?

Omeros Corporation operates within the biotechnology industry, a sector characterized by high growth potential and significant investment in research and development. The industry is driven by innovation in drug discovery and development, with a focus on addressing unmet medical needs. Omeros's focus on orphan indications and complement-mediated diseases positions it within a niche market with less competition but also higher regulatory hurdles. The competitive landscape includes major pharmaceutical companies and specialized biotech firms, all vying for market share in specific therapeutic areas. The biotechnology industry is experiencing growth driven by advancements in genomics, proteomics, and personalized medicine.

Who Are OMER's Key Customers?

• Patients suffering from orphan diseases.
• Hospitals and medical centers.
• Specialty pharmacies.
• Healthcare providers.

Omeros Corporation (OMER) Valuation Context

Valued at $1.35B, OMER is classified as a small-cap stock. Relative to its peer group, OMER's quantitative score of 31/100 is below the peer average of 76/100.

OMER Revenue & Earnings Trend

In Q2 2026, OMER generated $28.5M in top-line revenue, marking a sequential increase of 188.4%. The company recorded net income of $13.2M, with diluted EPS of $0.15.

Company Profile

Omeros Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Gregory A. Demopulos. OMER has traded publicly since 2009.

Return on equity for Omeros Corporation stands at -54.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 30.1%, showing how much profit it generates from its asset base. OMER trades at a trailing price-to-earnings ratio of 8.05, below the Healthcare sector average of ~23x. Its free cash flow yield is -13.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 12.4%, the inverse of the P/E and a quick read on earnings relative to price.

Omeros Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.12 places it in the distress zone, a signal of elevated financial risk.

Omeros Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 119.4% above estimates on average.

Wall Street analysts project Omeros Corporation revenue of about $68.0M for fiscal 2026, with EPS near $-0.04.

OMER Financials

OMER Latest News

OMER Analyst Consensus

OMER MoonshotScore

Latest Omeros Corporation Analysis

What Investors Ask About Omeros Corporation (OMER) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources